Is Medicamen Biotec overvalued or undervalued?

Oct 10 2025 08:05 AM IST
share
Share Via
As of October 9, 2025, Medicamen Biotec is considered overvalued with a PE ratio of 44.10 and poor stock performance, significantly lagging behind its peers and the Sensex.
As of 9 October 2025, Medicamen Biotec's valuation grade has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently deemed overvalued, with a PE ratio of 44.10, an EV to EBITDA ratio of 29.82, and a PEG ratio of 2.18. These figures suggest that the stock is trading at a premium compared to its earnings growth potential.

In comparison to its peers, Medicamen Biotec's valuation appears high; for instance, Sun Pharma has a PE ratio of 34.69, while Cipla stands at a more attractive 22.68. Furthermore, the company's recent stock performance has been underwhelming, with a year-to-date return of -39.47%, significantly lagging behind the Sensex's gain of 5.16% during the same period. This combination of high valuation ratios and poor relative performance reinforces the conclusion that Medicamen Biotec is overvalued in the current market.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News